Overcoming Native Macrolide and Acquired Multidrug-Resistant Pseudomonas aeruginosa with Azithromycin and Polymyxin B Nonapeptide

Aoi Kimishima; Hidehito Matsui; Kazunari Sakai; Masako Honsho; Sota Honma; Miho Sugamata; Naozumi Kondo; Serino Maruyama; Paul Wasuwanich; Kamrun Naher; Naoaki Arima; Kazutoyo Abe; Hideaki Hanaki; Yukihiro Asami

doi:10.1248/bpbreports.6.4_141

Report

Overcoming Native Macrolide and Acquired Multidrug-Resistant Pseudomonas aeruginosa with Azithromycin and Polymyxin B Nonapeptide

Aoi Kimishima, Hidehito Matsui, Kazunari Sakai, Masako Honsho, Sota Honma, Miho Sugamata, Naozumi Kondo, Serino Maruyama, Paul Wasuwanich, Kamrun Naher, Naoaki Arima, Kazutoyo Abe, Hideaki Hanaki, Yukihiro Asami

Author information

Aoi Kimishima
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Hidehito Matsui
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Kazunari Sakai
Research Management Department, Kowa Company Ltd.
Masako Honsho
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Sota Honma
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Miho Sugamata
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Naozumi Kondo
Graduate School of Infection Control Sciences, Kitasato University
Serino Maruyama
Graduate School of Infection Control Sciences, Kitasato University
Paul Wasuwanich
University of Florida College of Medicine
Kamrun Naher
Ōmura Satoshi Memorial Institute, Kitasato University
Naoaki Arima
Research Management Department, Kowa Company Ltd.
Kazutoyo Abe
Research Management Department, Kowa Company Ltd.
Hideaki Hanaki
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University
Research Management Department, Kowa Company Ltd.
Yukihiro Asami
Graduate School of Infection Control Sciences, Kitasato University
Ōmura Satoshi Memorial Institute, Kitasato University

Keywords: azithromycin (AZM), polymyxin B nonapeptide (PMBN), Pseudomonas aeruginosa (P. aeruginosa), multidrug-resistant clinical isolates

JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2023 Volume 6 Issue 4 Pages 141-143

DOI https://doi.org/10.1248/bpbreports.6.4_141

Details

Abstract

Semi-synthetic antibiotic, azithromycin (AZM) does not show significant bactericidal activity against Pseudomonas aeruginosa (P. aeruginosa). We focused on potential for AZM as a multi targeting drug against P. aeruginosa and found combination of AZM and Polymyxin B nonapeptide (PMBN) to increase the permeability of the outer membrane. This combination is effective for P. aeruginosa including multidrug-resistance clinical isolates and shows 32-512-fold potentiation of the anti-P. aeruginosa activity of AZM. We found a great opportunity to create new anti-P. aeruginosa drug candidates based on AZM and PMBN.

Corresponding author

Register with J-STAGE for free!